martes, 22 de septiembre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· May 28, 2026

Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD

View original at globenewswire.com
Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD - BLA submission based on positive results from Phase 3 INDIGO trial - WALTHAM, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Obexelimab has been evaluated in eight clinical trials in a total of 383 subjects, including INDIGO, and was well tolerated with demonstrated clinical activity across all trials

    60% confidence

  • The INDIGO open label extension will further build upon the largest body of clinical data reported for IgG4-RD patients to date

    60% confidence

  • Zenas expects to report topline SLE Phase 2 trial results, including biomarker data, in the fourth quarter of 2026

    60% confidence

  • The BLA submission brings Zenas one step closer to delivering a meaningful treatment option to patients living with IgG4-RD; based on INDIGO clinical activity and safety profile, obexelimab may have an important role as a first-line therapy in long-term management of IgG4-RD

    60% confidence

  • Obexelimab met and demonstrated highly statistically significant activity compared to placebo on all four key secondary endpoints in INDIGO and was generally well tolerated

    60% confidence

  • Obexelimab demonstrated a highly statistically significant and clinically meaningful 56% reduction in the risk of IgG4-RD flare compared to placebo (Hazard Ratio 0.44, p=0.0005) during the 52-week randomized placebo-controlled period of INDIGO

    60% confidence

  • Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule BTK inhibitor that targets pathogenic B cells in both the periphery and CNS, and directly modulates macrophages and microglial cells, with potential to address compartmentalized inflammation and disease progression in MS

    60% confidence

  • ZB021 is a novel, potentially best-in-class, oral small molecule IL-17AA/AF inhibitor

    60% confidence

  • ZB022 is a preclinical, potentially best-in-class, oral, brain-penetrant, TYK2 inhibitor

    60% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Frontier AI Slowdown Call Splits Industry, Rattles Capex-Sensitive Markets
Anthropic's Dario Amodei publicly called for a coordinated global slowdown in frontier AI development, a stance Microsoft echoed with a 'humanist' AI code of conduct, but Nvidia and Meta's CEOs rejected any coordinated pause days later, exposing a widening rift between safety-focused and growth-focused AI leaders. The dispute landed amid growing financial scrutiny of AI infrastructure spending — a hyperscaler capex analysis, FTC warnings against antitrust waivers for AI firms, and an 8.6% single-day stock drop in GE Vernova tied directly to the slowdown remarks — signaling investors are newly nervous about whether the AI capex boom (including Alphabet's projected $701B revenue narrative) can be justified if the pace of development itself becomes contested.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,983
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,983 hechos verificados con la fuente5,304 documentos fuente archivados
Consulta estos datos → isubstrate.com
Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD — Source | Via News | es.VIA.NEWS